Key result
LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, effectively reduces blood pressure in small studies, though larger studies are needed to prove its effectiveness and safety.
Why the study?
Does LCZ696 reduce blood pressure in patients with arterial hypertension?
Does LCZ696 reduce blood pressure in patients with arterial hypertension?
This review highlights the potential of LCZ696 as a novel antihypertensive therapy, though larger studies are required to confirm its safety and efficacy.
LCZ696 may lower BP via NP pathways; leaves open its role in hypertension pending dedicated RCTs.
The need for novel antihypertensive therapies represents a continuous challenge. LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor that has been shown to enhance endogenous natriuretic peptide (NP) actions on neurohormonal activation. This effect seems to be additive to that of the renin-angiotensin-aldosterone system (RAAS) suppression, as impressively suggested in the PARADIGM HF study. LCZ696 has been shown to be effective in reducing blood pressure in several small studies; however, its effectiveness and safety remain to be proved in larger studies. This review summarizes the role of RAAS and NP system in the pathophysiology of hypertension and reviews the current data on the antihypertensive effects of LCZ696.
No takes yet. Share an insight, caveat, or question.
Katsi et al. (2015) conducted a review in arterial hypertension. LCZ696 was evaluated. LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, effectively reduces blood pressure in small studies, though larger studies are needed to prove its effectiveness and safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Hypertension managementMore from European Heart Journal - Cardiovascular Pharmacotherapy